These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34677272)

  • 1. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
    Dai WF; Arciero V; Craig E; Fraser B; Arias J; Boehm D; Bosnic N; Caetano P; Chambers C; Jones B; Lungu E; Mitera G; Potashnik T; Reiman A; Ritcher T; Beca JM; Denburg A; Mercer RE; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group
    Curr Oncol; 2021 Oct; 28(5):4174-4183. PubMed ID: 34677272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
    Dai WF; Craig E; Fraser B; Chambers A; Mai H; Brown MB; Earle CC; Evans WK; Geirnaert M; Taylor M; Trudeau M; Sperber D; Beca JM; Denburg A; Mercer RE; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
    Curr Oncol; 2021 Nov; 28(6):4645-4654. PubMed ID: 34898572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
    Dai WF; de Oliveira C; Blommaert S; Pataky RE; Tran D; Aurangzeb Z; Kendell C; Folkins C; Somayaji C; Dowden J; Cheung W; Strumpf E; Beca JM; McClure C; Urquhart R; McDonald JT; Alvi R; Turner D; Peacock S; Denburg A; Mercer RE; Muñoz C; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
    Curr Oncol; 2022 Mar; 29(3):2046-2063. PubMed ID: 35323365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned.
    Evans WK; Takhar P; McDonald V; Elias M; Binder L; Michaud S; Tadrous M; Muñoz C; Chan KKW
    Curr Oncol; 2022 Aug; 29(8):5616-5626. PubMed ID: 36005181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
    Takhar P; Geirnaert M; Gavura S; Beca J; Mercer RE; Denburg A; Muñoz C; Tadrous M; Parmar A; Dionne F; Boehm D; Chambers C; Craig E; Trudeau M; Cheung MC; Houlihan J; McDonald V; Pechlivanoglou P; Taylor M; Wasylenko E; Wranik WD; Chan KKW
    Curr Oncol; 2024 Apr; 31(4):1876-1898. PubMed ID: 38668044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
    Parmar A; Dai WF; Dionne F; Geirnaert M; Denburg A; Ahuja T; Beca J; Bouchard S; Chambers C; Hunt MJ; Husereau D; Lungu E; McDonald V; Mercer RE; Mitera G; Muñoz C; Naipaul R; Peacock S; Potashnik T; Tadrous M; Takhar P; Taylor M; Trudeau M; Wasney D; Gavura S; Chan KKW
    Curr Oncol; 2023 Mar; 30(4):3776-3786. PubMed ID: 37185399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of real-world evidence from different data sources in health technology assessment.
    Graili P; Guertin JR; Chan KKW; Tadrous M
    J Pharm Pharm Sci; 2023; 26():11460. PubMed ID: 37529633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key learnings from Institute for Clinical and Economic Review's real-world evidence reassessment pilot.
    Jaksa A; Bloudek L; Carlson JJ; Shah K; Chen Y; Patrick AR; McKenna A; Campbell JD
    Int J Technol Assess Health Care; 2022 Mar; 38(1):e32. PubMed ID: 35357284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-making.
    Tadrous M; Aves T; Fahim C; Riad J; Mittmann N; Prieto-Alhambra D; Rivera DR; Chan K; Lix LM; Kent S; Dawoud D; Guertin JR; McDonald JT; Round J; Klarenbach S; Stanojevic S; De Vera MA; Strumpf E; Platt RW; Husein F; Lambert L; Hayes KN
    J Clin Epidemiol; 2024 Dec; 176():111545. PubMed ID: 39322123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 6.
    Simpson A; Ramagopalan SV
    J Comp Eff Res; 2022 May; 11(7):473-475. PubMed ID: 35261285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries.
    Bharmal M; Katsoulis I; Chang J; Graham A; Stavropoulou A; Jhingran P; Pashos CL
    Future Oncol; 2024; 20(21):1467-1478. PubMed ID: 38573230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop.
    Claire R; Elvidge J; Hanif S; Goovaerts H; Rijnbeek PR; Jónsson P; Facey K; Dawoud D
    Front Pharmacol; 2023; 14():1289365. PubMed ID: 38283835
    [No Abstract]   [Full Text] [Related]  

  • 18. Health Technology Agency insights: informing modification of a qualitative benefit risk framework for Health Technology Reassessment of prescription medications.
    Maloney MA; Schwartz L; O'Reilly D; Levine M
    Int J Technol Assess Health Care; 2019; 35(5):384-392. PubMed ID: 31524113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
    Sievers H; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.